Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Trial ID or NCT#
Status
RECRUITING
Purpose
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Official Title
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Eligibility Criteria
- - Histologically confirmed diagnosis of MF or SS - Stage IB, II-A, II-B, III, or IV; - Participants who have failed at least one prior course of systemic therapy (e.g., interferon, bexarotene, photopheresis, anti-neoplastic chemotherapy). Psoralen plus ultraviolet light therapy (PUVA) is not considered a systemic therapy.
- - Current evidence of large cell transformation; - Prior treatment with mogamulizumab; - History of allogeneic transplant.
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Kumari Khushboo
View on ClinicalTrials.gov
